Cambridge Cognition Expands Partnership with Actinogen for Alzheimer’s Trial

Cambridge Cognition Holdings ( (GB:COG) ) has provided an announcement.

Cambridge Cognition Holdings has expanded its collaboration with Actinogen Medical Limited for the Phase 2b/3 trial of Alzheimer’s treatment, XanaMIA. This partnership involves the use of Cambridge Cognition’s digital suite, including CANTAB and eCOA, to ensure precise clinical measurements, which underscores the effectiveness of their solutions in Alzheimer’s research. With dementia affecting millions globally, this trial is crucial in evaluating the therapeutic benefits of Actinogen’s emestedastat in slowing Alzheimer’s progression. The collaboration enhances data quality and scientific validity, reinforcing Cambridge Cognition’s role in innovative neurological research.

More about Cambridge Cognition Holdings

Cambridge Cognition is a brain health software group specializing in digital health products that enhance brain health research and treatment. The company offers products such as CANTAB assessments, an eCOA platform, rater training services, and quality assurance tools, which collectively improve clinical trial outcomes and efficiency in healthcare and pharmaceuticals.

YTD Price Performance: 6.67%

Average Trading Volume: 61,692

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £16.75M

For an in-depth examination of COG stock, go to TipRanks’ Stock Analysis page.